Patients With Upper Gastro-intestinal Symptoms Clinical Trial
— GERD Q NISOfficial title:
Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt
| Verified date | October 2014 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Egypt: Institutional Review Board |
| Study type | Observational |
The purpose of this study is to calculate the prevalence of gastroesophageal reflux disease (GERD) by mean of GERD-Q questionnaire in patients with upper gastrointestinal tract symptoms in Egypt.
| Status | Completed |
| Enrollment | 3170 |
| Est. completion date | July 2014 |
| Est. primary completion date | July 2014 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - 18 years and above - Attending the medical office and reporting symptoms suggestive of upper gastrointestinal tract symptoms such as heartburn/regurgitation, abdominal pain, bloating, belching and nausea/vomiting. Exclusion Criteria: - Participating on a clinical trial during the last 3 months. - Patients not able to read and/or understand the GERD-Q questionnaire. - Patients already included in the study in other participating site. - Patients taking PPIs or H2blockers in the l |
Time Perspective: Cross-Sectional
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Research Site | Al MENIA | |
| Egypt | Research Site | Alex | |
| Egypt | Research Site | Asuit | |
| Egypt | Research Site | Aswan | |
| Egypt | Research Site | Banha | |
| Egypt | Research Site | Cairo | |
| Egypt | Research Site | Domiaat | |
| Egypt | Research Site | Hurghada | |
| Egypt | Research Site | Ismailia | |
| Egypt | Research Site | Kafr el-Sheikh | |
| Egypt | Research Site | Kalubia | |
| Egypt | Research Site | Luxor | |
| Egypt | Research Site | Mahala | |
| Egypt | Research Site | Mansoura | |
| Egypt | Research Site | Menofia | |
| Egypt | Research Site | Port-Saeed | |
| Egypt | Research Site | Qena | |
| Egypt | Research Site | Sharkiah | |
| Egypt | Research Site | Sohag | |
| Egypt | Research Site | Suiz | |
| Egypt | Research Site | Tanta |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of patients scoring = 8 in GERD-Q | Percentage of patients scoring = 8 in GERD-Q will be considered as suffering from GERD. The GERD-Q is a potentially useful tool for family practitioners and other health care professionals in diagnosing and managing GERD without initial specialist referral or endoscopy. The Egyptian-validated version of the GERD-Q will be used for the study purposes. |
baseline | No |
| Secondary | Socio-demographic characteristics of patients diagnosed with gastroesophageal reflux disease (GERD) | Descriptive analysis of socio-demographic characteristics of patients diagnosed with gastroesophageal reflux disease (GERD) in Egypt. | baseline | No |
| Secondary | Treatment patterns in patients diagnosed with gastroesophageal reflux disease (GERD) | Descriptive analysis of treatment patterns in patients diagnosed with gastroesophageal reflux disease (GERD) in Egypt. | baseline | No |